What is the 13F Pro Quality Score for AURA?

13F Pro ranks Aura Biosciences, Inc. (AURA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AURA's current score at https://13fpro.ai/research/AURA (free sign-up required for the full ranking).

Where does 13F Pro source AURA data?

All Aura Biosciences, Inc. fundamentals and ownership data come directly from SEC EDGAR. Aura Biosciences, Inc. files with the SEC under CIK 1501796. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AURA in?

Aura Biosciences, Inc. (AURA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AURA research updated on 13F Pro?

AURA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aura Biosciences, Inc.(AURA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1501796 AURA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

AURA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Aura Biosciences, Inc. (AURA), a Healthcare sector company. AURA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Aura Biosciences, Inc. reports net income of $-33.7M, free cash flow of $-30.0M. Top institutional holders of AURA by reported 13-F value include Matrix Capital Management Company,, Frazier Life Sciences Management, L.P., ADAGE CAPITAL PARTNERS GP, L.L.C., based on the most recent SEC filings. AURA trades on the Nasdaq exchange and files with the SEC under CIK 1501796. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aura Biosciences, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-33.7M

Free Cash Flow

Q1 2026

$-30.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-22.2% YoY

$-106.2MFY 2025

FY22 $-58.8MFY23 $-76.4MFY24 $-86.9MFY25 $-106.2M

Operating Income

-17.3% YoY

$-112.8MFY 2025

FY22 $-60.3MFY23 $-85.0MFY24 $-96.1MFY25 $-112.8M

EPS (Diluted)

-0.6% YoY

$-1.76FY 2025

FY22 $-1.96FY23 $-1.93FY24 $-1.75FY25 $-1.76

Total Assets

-7.2% YoY

$169.4MFY 2025

FY22 $223.9MFY23 $255.1MFY24 $182.5MFY25 $169.4M

Op. Cash Flow

-6.2% YoY

$-84.7MFY 2025

FY22 $-54.6MFY23 $-63.8MFY24 $-79.8MFY25 $-84.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-106.2M -22.2%	$-86.9M -13.8%	$-76.4M -30.0%	$-58.8M -66.7%	$-35.3M -58.7%	$-22.2M
Operating Income	$-112.8M -17.3%	$-96.1M -13.1%	$-85.0M -41.0%	$-60.3M -71.0%	$-35.3M -58.7%	$-22.2M
EPS (Diluted)	$-1.76 -0.6%	$-1.75 +9.3%	$-1.93 +1.5%	$-1.96 +78.1%	$-8.95	—
Total Assets	$169.4M -7.2%	$182.5M -28.5%	$255.1M +13.9%	$223.9M +39.9%	$160.0M +624.0%	$22.1M
Operating Cash Flow	$-84.7M -6.2%	$-79.8M -25.0%	$-63.8M -16.9%	$-54.6M -68.5%	$-32.4M -33.3%	$-24.3M

AI Insight: AURA Financial Trends

Cash burn accelerated sharply in Q1 2026, with operating cash outflow hitting -$30M — the worst in eight quarters — while equity eroded to $107M.

• Operating cash outflow worsened from -$20M in Q3 2025 to -$30M in Q1 2026, the steepest single-quarter deterioration in the dataset.

• Equity has declined from $191M in Q2 2024 to $107M in Q1 2026, a cumulative $84M erosion over eight quarters.

• Operating losses had stabilized near -$27M to -$28M across Q3–Q4 2025 before spiking to -$35M in Q1 2026.

⚠ At the Q1 2026 burn rate of ~$30M/quarter, the $107M equity base implies limited runway without additional capital raises.

⚠ No revenue has appeared in any reported quarter; any first commercial revenue would be a critical positive inflection to monitor.

AI Insight: AURA Ratio Trends

Return metrics have deteriorated sharply, with ROE deepening to -125.6% and ROA to -97.9% in Q1 2026, signaling accelerating cash burn for this pre-revenue biotech.

• ROE worsened from -42.5% in Q2 2024 to -125.6% in Q1 2026, reflecting sustained and deepening net losses relative to equity.

• ROA deteriorated from -37.3% in Q2 2024 to -97.9% in Q1 2026, indicating declining asset efficiency as cash is consumed.

• ROIC reached its worst recorded level of -90.8% in Q1 2025 before a partial recovery to -65.5% in Q2 2025, then re-worsened to -79.6% in Q4 2025.

⚠ ROE and ROA hit new lows in Q1 2026 (-125.6% and -97.9%), suggesting quarterly burn rate is accelerating — cash runway is a key concern.

⚠ OpMargin, NPM, and D/E data are absent throughout; inability to assess leverage or operating cost trajectory limits full risk visibility.

Get alerted when AURA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aura Biosciences, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AURA

Matrix Capital Management Company, LP
$46.3M6,922,870 sh
Frazier Life Sciences Management, L.P.
$34.1M5,100,000 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$32.7M4,881,125 sh
Long Focus Capital Management, LLC
$30.9M4,619,582 sh
SUVRETTA CAPITAL MANAGEMENT, LLC
$29.3M4,372,884 sh
BlackRock, Inc.
$24.0M3,586,640 sh
Medicxi Ventures Management (Jersey) Ltd
$20.3M3,039,892 sh
VANGUARD CAPITAL MANAGEMENT LLC
$15.0M2,243,828 sh
Nantahala Capital Management, LLC
$14.2M2,117,697 sh
FRANKLIN RESOURCES INC
$13.9M2,072,726 sh

Fund	Value	Shares
Matrix Capital Management Company, LP	$46.3M	6,922,870
Frazier Life Sciences Management, L.P.	$34.1M	5,100,000
ADAGE CAPITAL PARTNERS GP, L.L.C.	$32.7M	4,881,125
Long Focus Capital Management, LLC	$30.9M	4,619,582
SUVRETTA CAPITAL MANAGEMENT, LLC	$29.3M	4,372,884
BlackRock, Inc.	$24.0M	3,586,640
Medicxi Ventures Management (Jersey) Ltd	$20.3M	3,039,892
VANGUARD CAPITAL MANAGEMENT LLC	$15.0M	2,243,828
Nantahala Capital Management, LLC	$14.2M	2,117,697
FRANKLIN RESOURCES INC	$13.9M	2,072,726

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AURA on your watchlist

Track score changes the day Aura Biosciences, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AURA a good stock to buy?

13F Pro's AI-powered analysis of Aura Biosciences, Inc. (AURA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AURA are available on the AURA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AURA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AURA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aura Biosciences, Inc.'s investment landscape.